Lipella Pharmaceuticals Azioni (NASDAQ: LIPO)

Ultime notizie per Lipella Pharmaceuticals (NASDAQ:LIPO) Azioni

Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals Inc

Lipocine Inc

enCore Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EU#NASDAQ">EU</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/EU#TSXV">EU</a>) (the "Company" or "enCore"), announced today the results of the most successful month at the Alta Mesa In-Situ Recovery Uranium Central Processing Plant ("CPP") since commencing operations in June 2024. Following previously announced improvements to operations (see <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4399711-1&amp;h=2814273370&amp;u=https%3A%2F%2Fencoreuranium.com%2Fnews%2Fencore-energy-expands-uranium-extraction-capacity-at-alta-mesa-accelerated-wellfield-development-underway%2F&amp;a=EU+NR+dated+March+13%2C+2025">EU NR dated March 13, 2025</a>) with the goal of expanding uranium extraction, decreasing unnecessary costs and increasing efficiency, the Company captured 50,000 pounds of uranium ("U3O8") in the last 26 days in March 2025.&nbsp; With a healthy treasury including unencumbered cash, inventory and marketable securities of ~$40 million USD, the Company continues to improve Alta Mesa CPP operations and the wellfield development program, which is now on track to meet 2025 contract projections. The Company also announced the appointment of Rob Willette, Acting Chief Executive Officer ("A/CEO"), to the Board of Directors and the promotion of Daniel Calderon to Director of Texas Operations. &nbsp;Mr. Willette will hold the Board seat dedicated to the Chief Executive Officer until such time a permanent appointment is made.
 &nbsp;

News

TSXV:EU

enCore Energy Boosts Production, Appoints Acting CEO Rob Willette to Board Amid Strong Cash Reserves, Hits Uranium Output Milestone With 50,000 Pounds Captured in March

cbdMD initiated this process in March 2021, with the submission of a comprehensive dossier detailing the ingredient's identity, quality, stability, hemp sourcing, extraction controls, labeling, testing requirements, usage instructions, and extensive safety data. In February 2022, cbdMD became the first U.S. brand to receive dossier validation. Since then, cbdMD has worked closely with the FSA, actively addressing inquiries to expedite the regulatory review process.

Health Care

General

YCBD

Cbdmd Announces That Food Dossier Has Advanced To The Last Phase Of Regulatory Assessment With The UK Food Standards Agency, Nearing Final Approval

EON Resources Inc. (NYSE:<a href="https://www.benzinga.com/stock/EONR#NYSE">EONR</a>) ("EON" or the "Company") is an independent upstream energy company with oil and gas properties in the Permian Basin. Given the current volatility in the market, the Company's contractual hedging program mitigates the negative impact of reduced oil price risk through the end of CY 2025.
Approximately 70% of the Company's oil production is contractually hedged.
Hedge prices the Company receives are from $70.10 to $70.50 per barrel.
The hedges are established and fixed in volume and price for the next 9 months.
"EON has a very responsible hedging program designed to protect the Company from volatile swings in oil prices as we have witnessed this week apparently driven by the expected increase in oil production by Saudi Arabia," said Mitchell B. Trotter, CFO of EON. "While we do not believe that the current oil price volatility will last for an extended period of time, our hedging program mitigates a negative impact to our financial results."

EONR

EON Resources Locks In Oil Prices at $70+ Through 2025 to Guard Against Market Volatility

HC Wainwright &amp; Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and raises the price target from $15 to $16.

Price Target

Analyst Ratings

ANGO

HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $16

<a href="https://www.globenewswire.com/Tracker?data=Yw-TWCZN9-grHtHI6xQ1MISsc5A_cnAd6iOP9HS2de_E9bO6kmRPpQ7-DdhCIp1XU_MLP8EPDO09LPQydV9zw0TvgUE4ojq7agmELTp5-SL1MHzrzstoyetmyPIknCr7">Plymouth Industrial REIT, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>) (the "Company" or "Plymouth") provided an activity update for the first quarter of 2025. The Company also announced details for its first quarter earnings conference call and webcast to be held on May 2, 2025.
Jeff Witherell, Chief Executive Officer and Co-Founder of Plymouth, noted, "Our strong leasing activity in the first quarter underscores the continued demand for well-located, functional industrial space across our markets. Additionally, our acquisition activity remains disciplined and strategic, as we continue to expand our footprint in key logistics hubs with assets that we expect will offer immediate cash flow and long-term value creation."
Leasing Activity Leases commencing during the first quarter ended March 31, 2025, all of which have terms of at least six months, totaled an aggregate of 2,437,267 square feet. These leases included 1,540,756 square feet of renewal leases and 896,511 square feet of new leases. Excluding the effect of the previously announced executed two-year lease at our 769,500-square-foot Class A building in St. Louis (the "St. Louis lease") that commenced on January 15, 2025, rental rates under these leases reflect a 16.2% increase on a cash basis with renewal leases reflecting a 15.0% increase on a cash basis and new leases reflecting a 22.1% increase on a cash basis. Including the St. Louis lease, the overall rental rates would have increased 9.6% on a cash basis and new leases would have increased 0.9% on a cash basis.
Same store occupancy at March 31, 2025, was 94.7%.&nbsp;&nbsp; Total portfolio occupancy at March 31, 2025, was 94.3% which reflects changes from last quarter including a 210-basis-point positive impact from the St. Louis lease, a 45-basis-point positive impact from leasing in in Cleveland, a 15-basis-point positive impact from acquisitions in Cincinnati and Atlanta markets and a net 70-basis-point negative impact from other leasing activity in the quarter.
Executed leases that will commence during 2025, all of which have terms of at least six months, totaled an aggregate of 4,652,684 square feet. These leases, which represent 56.3% of total 2025 expirations, include 3,731,230 square feet of renewal leases (30.0% of these renewal leases were associated with contractual renewals; there only remains a potential of 120,641 square feet of contractual renewals left in 2025) and 921,454 square feet of new leases, of which 740,487 square feet was vacant at the start of 2025. Excluding the effect of the St. Louis lease, rental rates under these leases reflect a 21.8% increase on a cash basis with renewal leases reflecting a 14.7% increase in rental rates on a cash basis and new leases reflecting a 15.3% increase on a cash basis. Including the St. Louis lease, the overall rental rates would have increased 12.1% on a cash basis and new leases would have increased 1.7% on a cash basis.
Acquisition Activity During the first quarter of 2025, Plymouth closed on the acquisition of six industrial buildings totaling 801,161 square feet for a total of $65.1 million and a weighted average initial estimated net operating income ("NOI") yield of 6.8%. Taken together, these 100% leased properties feature a weighted average remaining lease term of 4.4 years. The first quarter activity comprises the following:
<ul>
<li>263,000 square foot industrial building in Cincinnati, Ohio for $23.3 million and an initial estimated NOI yield of 6.7%.</li>
<li>Madison International's 98% joint venture interest in a 297,583 square-foot warehouse facility in Atlanta, Georgia with 100% occupancy for $23.9 million and an initial estimated NOI yield of 6.8%.</li>
<li>The second tranche of the previously announced Cincinnati small bay industrial portfolio consisting of four buildings totaling 240,578 square feet for $17.9 million and representing an estimated NOI yield of 7.0%. &nbsp;</li>
</ul>
Market Portrait Series&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; We issued our second Market Portrait with Avison Young highlighting the Memphis industrial market - America's Distribution Center. The Portrait can be found on our corporate website under <a href="https://www.globenewswire.com/Tracker?data=WQ1381YMiTO9gZWqd6tj-ZMNvBYqYE254AygMFMeZN-NmRG6lwAoC9wkc5l3i0enOvFVcIPhVSa3mZAMfWPTGJ-SH_EgQtJUEfOrT84QgHfbXvBabSov5t2KEBwWZyhP5rDZEB_m8nKSLeJgBwdHyw==">Portfolio / Portfolio Map / Memphis</a>.
Known as "America's Distribution Center," Memphis' freight transportation infrastructure connects companies to nearly every major national and international market. Home to the FedEx World SuperHub, Memphis offers local companies an advantage as the cutoff time to drop off packages for next day delivery is later than counterparts in other U.S. cities. The market is served by five Class 1 railroads and is a key market where the eastern railroads CSX and NS can interconnect with western railroads BNSF and UP. In addition, Canadian National offers a key connection from the Gulf Coast to Canada via Memphis. The Memphis region is serviced by six interstate highways, the most significant being I-55 connecting Chicago to New Orleans and I-40 connecting California to North Carolina.
As of December 31, 2024, Memphis was our largest wholly-owned single market position with 63 buildings across approximately 6.4 million square feet.

PLYM

Plymouth REIT Signs Over 2.4M Square Feet in Q1 Leases, Expands Footprint With $65M in New Property Deals, Boosts Occupancy in Key Logistics Hubs

<ul>
<li>TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia</li>
<li>TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two pivotal double-blind randomized Phase 3 studies</li>
<li>FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia</li>
<li>If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years</li>
</ul>

Biotech

TNXP

Tonix Pharmaceuticals Presented Data And Analyses Of TNX-102 SL Treatment Effects On Fibromyalgia At The American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

BRKR

Bruker Launches 1.3 GHz High-Resolution Nuclear Magnetic Resonance System

Needham analyst Bernie McTernan reiterates DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and maintains $65 price target.

Reiteration

DKNG

Needham Reiterates Buy on DraftKings, Maintains $65 Price Target

Bruker Launches Fourier 80 Multinuclear Benchtop FT-NMR Spectrometer To Enable  X-Nucleus Observations And various 2D Experiments

ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA's strategic advantage through fully U.S.-based manufacturing operations, commercialization and end-market sales, and a vertically integrated U.S.-based supply chain.
"ADMA is a U.S.-based company with all manufacturing operations, end-market sales, and customer engagements conducted exclusively within the United States," said Adam Grossman, President and Chief Executive Officer of ADMA. "The tariffs that have been implemented on foreign goods, services and manufacturing should have no impact on ADMA and its supply chain or production operations. The Company's vertically integrated supply chain is fully domiciled in the U.S., providing end-to-end domestic control over sourcing, manufacturing, and distribution. Our strategic infrastructure not only ensures enhanced supply chain robustness, resilience and regulatory compliance, but also aligns with increasing federal and private sector preferences for U.S.-made products and services. By maintaining complete operational control within the U.S., ADMA is uniquely well-positioned to capitalize on national economic incentives and deliver reliable, secure, and high-quality offerings to its domestic customer base."

Government

Regulations

ADMA

ADMA Highlights US-Based Supply Chain as Key Advantage in Tariff Era

MRNA

Moderna Will Present Research Across Multiple Infectious Disease Areas, Including COVID-19, Influenza, Respiratory Syncytial Virus, Cytomegalovirus, Norovirus, And mpox, At The European Society Of Clinical Microbiology And Infectious Diseases

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

BEAM

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

<ul>
<li>Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days.</li>
<li>Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist.</li>
<li>iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026.</li>
</ul>

IBIO

iBio's Non-GLP Non-human Primate Pharmacokinetics Study Suggests IBIO-600, Anti-myostatin Antibody Designed For Subcutaneous Administration, Could Provide A Significantly Extended Half-life In Humans And A Weight Loss Treatment Option While Preserving And Promoting Muscle Growth

Gilat Satellite Networks Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>, TASE: GILT))), a worldwide leader in satellite networking technology, solutions and services, announced today that Gilat Defense was awarded a contract to provide ongoing sustainment and support services for Satellite Transportable Terminal (STT) units deployed worldwide in support of U.S. Department of Defense (DoD) customers. The contract includes a base program with options to extend up to five years, totaling up to $23 million.
Under the agreement, Gilat Defense will deliver critical program management, field services, and technical support, ensuring operational readiness and continued reliability of these vital communication assets.

GILT

Gilat Wins $23M Deal to Support Satellite Terminals for US Defense Department

<ul>
<li>Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks.</li>
<li>19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks.</li>
<li>20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks.</li>
<li>Regulatory submissions in the U.S. and EU anticipated to be completed in the third quarter of 2025.</li>
</ul>

RYTM

Rhythm Pharmaceuticals' Phase 3 TRANSCEND Trial Of Setmelanotide For Acquired Hypothalamic Obesity, Met Its Primary Endpoint With Statistically Significant And Highly Clinically Meaningful Reduction In Body Mass Index In Adult And Pediatric Patients Versus Placebo

United Homes Posts 22.9% Decrease In Q1 Net New Orders

Republic Airways Holdings Inc. and Mesa Air Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) today announced that they have entered into a definitive agreement to merge and create a leading publicly-traded regional airline company in an all-stock transaction. Upon closing, the combined company will be renamed Republic Airways Holdings Inc. and is expected to remain NASDAQ-listed under the new ticker symbol "RJET".

MESA

Republic Airways and Mesa Air Merge in All-Stock Deal to Create New Nasdaq-Listed Airline

<ul>
<li>While the Company's presence in the U.S. opioids market is very small, the Company has agreed to this settlement to provide closure on these matters. This settlement is in no way an admission of wrongdoing or liability.</li>
<li>Under the agreed upon framework, depending on the level of participation in the settlement, the Company would pay up to a maximum of $335 million, consisting of annual payments over a nine-year period of between approximately $27.5 and $40 million each, to help support state and local efforts to address opioid-related issues. The Company had already accrued an estimate in respect of a potential settlement, which is reflected in the Company's annual report on Form 10-K for the year ended December 31, 2024. &nbsp;</li>
<li>The Company will also continue its longstanding role of working to identify solutions to address pressing public health challenges like those relating to opioids. For example, the Company manufactures a generic injectable version of the life-saving overdose reversal drug, naloxone, as well as a generic buprenorphine/naloxone product used for the treatment of opioid addiction. The Company is also developing a novel delivery for meloxicam, a non-opioid pain medication. &nbsp;</li>
</ul>

Legal

VTRS

Viatris Reached A Nationwide Settlement Framework To Resolve Opioid-related Claims By States, Local Governments, And Tribes Against The Company And Certain Of Its Subsidiaries, The Company Would Pay Up To A Maximum Of $335M

HC Wainwright &amp; Co. analyst Scott Buck maintains Knightscope (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) with a Buy and lowers the price target from $16 to $12.

Comments

Lipella Pharmaceuticals

Notizie

Ultime notizie per Lipella Pharmaceuticals (NASDAQ:LIPO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO